A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

NCT01352845 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
3301
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer